Information for patients
Learn about ongoing trials and how to participate.
Pulse Heart Institute: commitment to cardiovascular advancement
Leading the way in research, innovation and patient care
Pushing Past the Limits of Cardiovascular Care
At Pulse Heart Institute, we believe that providing our patients with the most sophisticated and effective cardiovascular treatments and state-of-the-art technology is just the beginning. Our commitment extends beyond today’s medicine. We strive to be leaders in the ongoing research that shapes the future of cardiovascular care. By actively participating in groundbreaking studies and embracing innovation, we play a crucial role in advancing cardiovascular medicine for generations to come.
Expanding Research Through Strategic Partnership
Pulse Heart Institute takes seriously our responsibility to ensure access to state-of-the-art and beyond-state-of-the-art cardiovascular care to patients from throughout the Pacific Northwest and beyond, who we are privileged to take care of in our communities. We were born out of a 2016 partnership with MultiCare built with a radical idea: to comprehensively support patients and clinicians so that they can participate in research studies without missing a beat in their busy days. This proved popular with both our patients and clinical teams, so in 2025, we took the next logical step: to launch the Pulse Heart Institute Center for Research and Innovation (“PHICRI” or “fih-kree”) to expand cardiovascular research and innovation throughout the region, enabling patients to participate closer to home.
Shaping the Future of Cardiovascular Medicine
Our mission is clear: to remain at the forefront of cardiovascular research and innovation, delivering not only exceptional medical care but also hope and improved outcomes for our patients. By fostering partnerships and embracing progress, Pulse Heart Institute continues to push the boundaries of what is possible in heart health.
Our cardiovascular studies encompass a wide range of therapeutic areas, reflecting our commitment to comprehensive research and patient care.
By investigating these diverse therapeutic areas, Pulse Heart Institute is able to deliver cutting-edge solutions and make meaningful advancements in cardiovascular medicine.
Our researchers are continuously adding studies to our panel, so please check back often to learn of new studies that have been added.
Contact the Pulse Heart Institute Center for Research and Innovation
Learn MoreActive research
-
Cardiovascular Disease/Coronary Disease
-
Trial Title: Evaluation of inclisiran versus placebo for the prevention of major adverse cardiovascular and limb events in patients undergoing percutaneous coronary intervention or peripheral endovascular intervention (VICTORION-Intervention)
Phase: 4
Disease: High Cholesterol (LDL)
Intervention/treatment: Inclisiran
Status: Enrolling
Primary Investigator: Dr. Ahmad Slim (Puyallup); Dr. Daniel Guerra (Tacoma)
NCT: 06909565
Trial Title: Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
Phase: 3
Disease: Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention/treatment: Obicetrapib
Status: Active, not enrolling
Primary Investigator: Dr. Uma Krishnan
NCT: 05202509
Trial Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
Phase: 3
Disease: Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention/treatment: Olpasiran
Status: Active, not enrolling
Primary Investigator: Dr. Vinay Malhotra
NCT: 05581303
Trial Title: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease
Phase: 3
Disease: Athersclerotic cardiovascular disease (ASCVD)
Intervention/treatment: Inclisiran
Status: Active, not enrolling
Primary Investigator: Dr. Ahmad Slim
NCT: 03705234
Trial Title: Long-Term Outcome and Quality Indicator (LOQI) Impella Registry
Phase: Registry; observational
Disease: Coronary Artery Disease (CAD)
Intervention/treatment:
Status: Active, not enrolling
Primary Investigator: Dr. Ravi Hira
Trial Title: DECIDE: AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD management
Phase: Registry; observational
Disease: Coronary Artery Disease (CAD)
Intervention/treatment:
Status: Active, not enrolling
Primary Investigator: Dr. Ahmad Slim
NCT: 06376851
Trial Title: A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 Prevent)
Phase: 3
Disease: High risk primary prevention
Intervention/treatment: Inclisiran
Status: Active, not enrolling
Primary Investigator: Dr. Ahmad Slim
NCT: 05739383
-
Cardiothoracic/Structural Heart Disease
-
Trial Title: On-X® aortic prosthetic heart valve low dose warfarin post approval clinical registry study
Phase: Registry; observational
Disease: Heart valve replacement
Intervention/treatment:
Status: Active, not enrolling
Primary Investigator: Dr. Michael Meyer
NCT: 02677974
-
Heart Failure
-
Trial Title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
Phase: 3
Disease: Heart failure & Obesity
Intervention/treatment: Maridebart cafraglutide
Status: Enrolling
Primary Investigator: Dr. Vinay Malhotra
NCT: 07037459
-
Heart Rhythm Disorders
-
Trial Title: ANT-010 (LILAC-TIMI); a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Abelacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral anticoagulation(LILAC)
Phase: III
Disease: Atrial fibrillation or Atrial Flutter
Intervention/treatment: Abelacimab
Status: Enrolling
Primary Investigator: Dr. Arun Sridhar
NCT: 05712200
Trial Title: REView of ProcEdural FactoRs and Outcomes after Atrial Fibrillation Ablation with Active Esophageal COOLing (EVERCOOL)
Phase: Registry; observational
Disease: Atrial fibrillation
Intervention/treatment:
Status: Active, not enrolling
Primary Investigator: Dr. Jeffrey Ho
NCT: 06354777
Trial Title: The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO™ System Use in Conjunction with VISITAG SURPOINT™ Module for the treatment of symptomatic drug refractory paroxysmal atrial fibrillation (A nested sub-study of REAL AF registry)
Phase: Registry; observational
Disease: Atrial fibrillation
Intervention/treatment:
Status: Enrolling
Primary Investigator: Dr. Tariq Salam
NCT: 06324201
Trial Title: Real-world Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation Using Novel Contact Force Technologies: REAL AF Registry
Phase: Registry; observational
Disease: Atrial fibrillation
Intervention/treatment:
Status: Enrolling
Primary Investigator: Dr. Tariq Salam
NCT: 04088071
-
Imaging
-
Trial Title: DECIDE: AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD management
Phase: Registry; observational
Disease: Coronary Artery Disease (CAD)
Intervention/treatment:
Status: Active, not enrolling
Primary Investigator: Dr. Ahmad Slim
NCT: 06376851
-
Population Health/Cardiovascular Disease Prevention
-
Trial Title: Evaluation of inclisiran versus placebo for the prevention of major adverse cardiovascular and limb events in patients undergoing percutaneous coronary intervention or peripheral endovascular intervention (VICTORION-Intervention)
Phase: 4
Disease: High Cholesterol (LDL)
Intervention/treatment: Inclisiran
Status: Enrolling
Primary Investigator: Dr. Ahmad Slim (Puyallup); Dr. Daniel Guerra (Tacoma)
NCT: 06909565
Trial Title: Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
Phase: 3
Disease: Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention/treatment: Obicetrapib
Status: Active, not enrolling
Primary Investigator: Dr. Uma Krishnan
NCT: 05202509
Trial Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
Phase: 3
Disease: Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention/treatment: Olpasiran
Status: Active, not enrolling
Primary Investigator: Dr. Vinay Malhotra
NCT: 05581303
Trial Title: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease
Phase: 3
Disease: Atherosclerotic cardiovascular disease (ASCVD)
Intervention/treatment: Inclisiran
Status: Active, not enrolling
Primary Investigator: Dr. Ahmad Slim
NCT: 03705234
Trial Title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
Phase: 3
Disease: Heart failure & Obesity
Intervention/treatment: Maridebart cafraglutide
Status: Enrolling
Primary Investigator: Dr. Vinay Malhotra
NCT: 07037459
Trial Title: CQCZ484A12201: A randomized, double-blind, placebo-controlled, multicenter, 12 months treatment duration, dose finding study to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients
Phase: 2b
Disease: Hypertension
Intervention/treatment: QCZ484
Status: Enrolling
Primary Investigator: Dr. Vinay Malhotra
NCT: 06857955
Trial Title: DECIDE: AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD management
Phase: Registry; observational
Disease: Coronary Artery Disease (CAD)
Intervention/treatment:
Status: Active, not enrolling
Primary Investigator: Dr. Ahmad Slim
NCT: 06376851
Trial Title: A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 Prevent)
Phase: 3
Disease: High risk primary prevention
Intervention/treatment: Inclisiran
Status: Active, not enrolling
Primary Investigator: Dr. Ahmad Slim
NCT: 05739383
-
Vascular Disease
-
Trial Title: Evaluation of inclisiran versus placebo for the prevention of major adverse cardiovascular and limb events in patients undergoing percutaneous coronary intervention or peripheral endovascular intervention (VICTORION-Intervention)
Phase: 4
Disease: High Cholesterol (LDL)
Intervention/treatment: Inclisiran
Status: Enrolling
Primary Investigator: Dr. Ahmad Slim (Puyallup); Dr. Daniel Guerra (Tacoma)
NCT: 06909565
-
Other studies
-
No studies at this time. Please check back regularly for updates.
Participate in research
View Open Clinical Trials
Browse Open clinical trials
Through our research, Pulse Heart Institute patients and community members often have early access to promising medications and devices, therapies, and surgical techniques that offer types of care that otherwise would not be available.
Mentored research opportunities
Opportunities for research scholars, research fellows, and research assistants. Please submit a cover letter and CV describing your research experiences, current institution and training level, interests and objectives in a mentored research program.
Email the PHI Research Institute